Future Pak Submits Proposals to Acquire Theratechnologies Inc., Offering up to $255 Million in Total Value
Future Pak has submitted two formal proposals to acquire Theratechnologies (NASDAQ: THTX), with the latest offering $3.51 to $4.50 per share. The proposal values the deal at up to $255 million, consisting of:
- $205 million in cash at closing
- Up to $50 million in contingent value rights (CVR), including 50% of annual EGRIFTA® franchise gross profit above $30 million for three years
- A $10 million milestone payment if EGRIFTA gross profit exceeds $125 million over three years
The offer represents a 164% to 238% premium over Theratechnologies' closing price of $1.33 as of April 10, 2025. Despite the significant premium and multiple proposals, Future Pak reports minimal engagement from Theratechnologies. The transaction has no financing contingency and is supported by Colbeck Capital Management.
Future Pak ha presentato due proposte formali per acquisire Theratechnologies (NASDAQ: THTX), con l'ultima offerta di $3.51 a $4.50 per azione. La proposta valuta l'affare fino a $255 milioni, composto da:
- $205 milioni in contante al momento della chiusura
- Fino a $50 milioni in diritti di valore contingente (CVR), inclusi il 50% del profitto lordo annuale del franchise EGRIFTA® oltre i $30 milioni per tre anni
- Un pagamento di $10 milioni al raggiungimento di un obiettivo se il profitto lordo di EGRIFTA supera i $125 milioni in tre anni
L'offerta rappresenta un 164% a 238% di premio rispetto al prezzo di chiusura di Theratechnologies di $1.33 al 10 aprile 2025. Nonostante il significativo premio e le molteplici proposte, Future Pak riporta un coinvolgimento minimo da parte di Theratechnologies. La transazione non ha condizioni di finanziamento ed è supportata da Colbeck Capital Management.
Future Pak ha presentado dos propuestas formales para adquirir Theratechnologies (NASDAQ: THTX), con la última oferta de $3.51 a $4.50 por acción. La propuesta valora el acuerdo en hasta $255 millones, que consiste en:
- $205 millones en efectivo al cierre
- Hasta $50 millones en derechos de valor contingente (CVR), incluyendo el 50% de las ganancias brutas anuales de la franquicia EGRIFTA® por encima de $30 millones durante tres años
- Un pago de $10 millones si las ganancias brutas de EGRIFTA superan los $125 millones en tres años
La oferta representa un 164% a 238% de prima sobre el precio de cierre de Theratechnologies de $1.33 al 10 de abril de 2025. A pesar de la significativa prima y las múltiples propuestas, Future Pak informa de un compromiso mínimo por parte de Theratechnologies. La transacción no tiene contingencias de financiamiento y cuenta con el apoyo de Colbeck Capital Management.
Future Pak는 Theratechnologies (NASDAQ: THTX)를 인수하기 위해 두 가지 공식 제안을 제출했으며, 최신 제안은 주당 $3.51에서 $4.50입니다. 이 제안은 거래 가치를 최대 $255 백만으로 평가하고 있으며, 구성 요소는 다음과 같습니다:
- 마감 시 현금 $205 백만
- 3년 동안 $30 백만을 초과하는 EGRIFTA® 프랜차이즈 총 이익의 50%를 포함하여 최대 $50 백만의 조건부 가치 권리(CVR)
- EGRIFTA 총 이익이 3년 동안 $125 백만을 초과할 경우 $10 백만의 이정표 지급
이 제안은 2025년 4월 10일 기준으로 Theratechnologies의 종가인 $1.33에 대해 164%에서 238%의 프리미엄을 나타냅니다. 상당한 프리미엄과 여러 제안에도 불구하고 Future Pak은 Theratechnologies로부터 최소한의 참여를 보고하고 있습니다. 이 거래는 자금 조달 조건이 없으며 Colbeck Capital Management의 지원을 받습니다.
Future Pak a soumis deux propositions formelles pour acquérir Theratechnologies (NASDAQ: THTX), la dernière offre étant de $3.51 à $4.50 par action. La proposition évalue l'accord à un maximum de $255 millions, composé de :
- $205 millions en espèces à la clôture
- Jusqu'à $50 millions en droits de valeur contingente (CVR), y compris 50% du bénéfice brut annuel de la franchise EGRIFTA® au-dessus de $30 millions pendant trois ans
- Un paiement de $10 millions si le bénéfice brut d'EGRIFTA dépasse $125 millions sur trois ans
L'offre représente une prime de 164% à 238% par rapport au prix de clôture de Theratechnologies de $1.33 au 10 avril 2025. Malgré la prime significative et les multiples propositions, Future Pak fait état d'un engagement minimal de la part de Theratechnologies. La transaction n'a pas de condition de financement et est soutenue par Colbeck Capital Management.
Future Pak hat zwei formelle Vorschläge zur Übernahme von Theratechnologies (NASDAQ: THTX) eingereicht, wobei das neueste Angebot $3.51 bis $4.50 pro Aktie beträgt. Der Vorschlag bewertet den Deal auf bis zu $255 Millionen, bestehend aus:
- $205 Millionen in bar bei Abschluss
- Bis zu $50 Millionen in bedingten Wertrechten (CVR), einschließlich 50% des jährlichen Bruttogewinns der EGRIFTA®-Franchise über $30 Millionen für drei Jahre
- Eine Zahlung von $10 Millionen bei Erreichung eines Meilensteins, wenn der Bruttogewinn von EGRIFTA über drei Jahre $125 Millionen übersteigt
Das Angebot stellt eine 164% bis 238% Prämie gegenüber dem Schlusskurs von Theratechnologies von $1.33 am 10. April 2025 dar. Trotz der erheblichen Prämie und mehrerer Vorschläge berichtet Future Pak von minimalem Engagement seitens Theratechnologies. Die Transaktion hat keine Finanzierungsbedingungen und wird von Colbeck Capital Management unterstützt.
- Significant premium of 164-238% offered to shareholders
- Substantial cash component of $205M at closing
- Additional upside potential through $50M in CVR payments
- No financing contingency risk
- Strong financial backing from Colbeck Capital Management
- Minimal engagement from Theratechnologies' management
- Deal completion uncertainty due to lack of cooperation
- CVR payments dependent on future EGRIFTA performance
Insights
Future Pak's unsolicited acquisition proposal for Theratechnologies represents a significant premium of
The premium is substantial even by aggressive acquisition standards, suggesting Future Pak sees considerable unrealized value in Theratechnologies' assets. The CVR structure is particularly telling - by tying additional payments to EGRIFTA franchise performance above
Notably concerning is Theratechnologies' apparent lack of engagement despite receiving multiple premium offers. This public disclosure tactic by Future Pak is a classic move to apply shareholder pressure when management appears resistant. The absence of a financing contingency removes a common obstacle, making this a credible offer that the board has fiduciary responsibility to seriously evaluate.
For current shareholders, this represents a potential immediate value realization opportunity far above current market valuation, though the board may believe longer-term standalone prospects exceed even this premium offer. The market will likely bid up shares in anticipation of either this transaction or potentially competing offers now that Theratechnologies is effectively "in play."
This acquisition bid reveals strategic interest in Theratechnologies' commercial assets, particularly the EGRIFTA franchise for HIV-related lipodystrophy. The
The proposed performance thresholds—specifically gross profits exceeding
Future Pak's contract manufacturing background positions them to potentially streamline production costs while maintaining compliance with specialized biologic manufacturing requirements. This would directly enhance the gross profit metrics tied to their contingent payments.
For the broader pharmaceutical landscape, this represents continued interest in acquiring established commercial-stage assets with stable revenue streams, particularly in specialty markets with competition. The premium valuation highlights how public markets may be undervaluing certain pharmaceutical assets compared to their strategic worth to acquirers with complementary capabilities.
The proposal represents a total enterprise value of up to
-
$205 million -
Up to
$50 million -
50% of the annual EGRIFTA® franchise gross profit (defined as net sales minus cost of goods, perU.S. GAAP) above$30 million -
A
$10 million $125 million
-
This offer implies a
“To move this process forward efficiently and deliver compelling value to Theratechnologies’ shareholders, we have submitted multiple offers outlining a flexible and attractive framework,” said Nirav Patel, Chief Growth Officer at Future Pak. “We believe this proposal provides significant upside and a solid foundation for constructive dialogue, with the goal of achieving a mutually beneficial transaction.”
Despite repeated outreach and the submission of two detailed proposals—each offering a premium of more than
Future Pak confirms that the transaction would not be subject to a financing contingency and has the full support of its strategic financial partner, Colbeck Capital Management.
Future Pak has engaged Bourne Partners Securities LLC as financial advisor and Honigman LLP as legal advisor. Given access to standard due diligence materials, Future Pak believes it could reach a definitive agreement and announce a transaction within four to six weeks.
By publicly disclosing its interest, Future Pak hopes to encourage Theratechnologies shareholders to engage with the proposal and ensure that the Board fulfills its duty to pursue the highest value outcome available.
About Future Pak
Founded in 1977 and headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250411477925/en/
Investors and media may contact media@futurepak.com.
Source: Future Pak, LLC
FAQ
What is the total value of Future Pak's acquisition offer for Theratechnologies (THTX)?
What premium does Future Pak's offer represent for THTX shareholders?
What are the terms of the CVR payments in Future Pak's offer for THTX?
How long would it take Future Pak to complete the THTX acquisition?
